Takano Y

No ORCID on file · 6 papers in corpus · active 1997-2013

Study types

  • article 3
  • case-report 1

Condition tags

  • endometriosis 4
2013
PloS one ·doi:10.1371/journal.pone.0080359

Ovarian clear cell adenocarcinoma (CCC) is the second most common subtype of ovarian cancer after high-grade serous adenocarcinomas. CCC tends to develop resistance to the standard platinum-based chemotherapy, and has a poor prognosis when …

2013
Cell cycle (Georgetown, Tex.) ·doi:10.4161/cc.25950

PurposeExtracellular matrix metalloproteinase inducer (EMMPRIN) was reported to involve in the invasion and metastasis of malignancies by regulating the expression of vascular endothelial growth factor (VEGF) and matrix metalloproteinases (…

case-report 2010
International journal of clinical oncology ·doi:10.1007/s10147-010-0052-y

We present a case of clear cell carcinoma located in the diaphragm in a patient with a medical history of ovarian endometriosis. Ultrasonography revealed the presence of a 2.5-cm nodule on the surface of the liver in a 65-year-old woman. Sh…

article 2010
Pathology international ·doi:10.1111/j.1440-1827.2010.02573.x

Primary endometrioid adenocarcinoma rarely occurs in the vagina. Occasionally, endometrioid adenocarcinoma has a microglandular pattern. Herein, a case of primary endometrioid adenocarcinoma of the vagina with a microglandular pattern arisi…

article 1998
European journal of endocrinology ·doi:10.1530/eje.0.1380216

OBJECTIVE: Dienogest, a synthetic steroid with progestational activity, is used as a component of oral contraceptives and is currently being evaluated clinically for the treatment of endometriosis. The present study was conducted to confirm…

article 1997
Drugs under experimental and clinical research

Dienogest is an orally active synthetic steroid that is used for contraception and is currently being studied for the possible treatment of endometriosis. Earlier we demonstrated that dienogest had therapeutic effects on experimental endome…